Skip to main content

ABI and Invitrogen Join Forces on Labeling Reagents for Proteomics

NEW YORK, June 6 (GenomeWeb News) - Applied Biosystems and Invitrogen will co-market and re-sell their respective protein-labeling technologies for quantitative proteomics and biomarker studies, the companies said today.


Under the agreement, the companies will jointly sell ABI's iTRAQ and ICAT protein and peptide labeling reagents, and Invitrogen's new SILAC metabolomic labeling technology. ABI will also support Invitrogen's SILAC technology with software on its TOF/TOF mass spectrometers and plans to extend software support to other mass spec types.


In addition, the companies said they will co-develop and co-market protein sample preparation kits for mass spectrometry, as well as other reagents such as matrices, solubilizers, and calibrants.


Neither company disclosed financial terms of the agreement.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.